Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
More good news for men with castrate-resistant metastatic prostate cancer who have failed chemotherapy. Two new therapies have recently been approved for use in Australia, cabazitaxel (Jevtana) and abiraterone (Zytiga). Cabazitaxel was listed on PBS from 1st August 2012.
Yesterday, in the New England Journal of Medicine, the results of the phase 3 trial into the effectiveness of enzalutamide (formerly known as MDV3100) were published. Enzalutamide targets multiple steps in the androgen receptor signaling pathway, the major driver of prostate cancer growth. It is taken orally, once-daily.
Enzalutamide significantly prolonged survival of men with castrate-resistant metastatic prostate cancer after chemotherapy with a median increase in overall survival from 13.6 months to 18.4 months.
Clinical trials of enzalutamide in earlier stage prostate cancer are on-going.